OPR - Delayed Quote USD

ARGX May 2024 280.000 put (ARGX240517P00280000)

3.1000 0.0000 (0.00%)
As of December 22 at 10:21 AM EST. Market Open.
Key Events
Advanced Chart
Loading Chart for ARGX240517P00280000
DELL
  • Previous Close 3.1000
  • Open 3.1000
  • Bid 1.5000
  • Ask 6.3000
  • Strike 280.00
  • Expire Date 2024-05-17
  • Day's Range 3.1000 - 3.1000
  • Contract Range --
  • Volume 1
  • Open Interest 1

Recent News: ARGX

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
GlobeNewswire 12 days ago
Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4

Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4
Insider Monkey 29 days ago
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire last month
argenx Announces Annual General Meeting of Shareholders on May 7, 2024

argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GlobeNewswire last month
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
GlobeNewswire last month
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
Zacks last month
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
Zacks last month
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investor's Business Daily last month
Reasons to Invest in argenx (ARGX)

Reasons to Invest in argenx (ARGX)
Insider Monkey last month
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
GlobeNewswire last month
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4

Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
Insider Monkey last month
Should You be Confident in Your Investment in argenx SE (ARGX)?

Should You be Confident in Your Investment in argenx SE (ARGX)?
Insider Monkey last month
View More